Business Wire

NTT

18.12.2019 07:55:13 CET | Business Wire | Press release

Share
NTT Group Launches Compliance Management Solution Using Robotic Process Automation (RPA)

In recent times, there has been a growing demand for companies worldwide to strengthen their compliance and risk management. To help our clients manage these requirements, NTT Group, represented by NTT Advanced Technology Corporation (hereinafter, NTT-AT), Everis Spain S.L.U. (hereinafter, everis) of NTT DATA Corporation, itelligence AG (hereinafter, itelligence) of NTT DATA Corporation are announcing a compliance management solution using robotic process automation (RPA). This solution aggregates and analyses data from internal HR and compliance on-premise and cloud-based systems, supporting customer initiatives to strengthen responsibility and internal governance control. The NTT Group plans to start providing this service in the second quarter of 2020.

Due to stricter regulations across many industries, particularly the financial industry, businesses are facing the threat of multi-regime controls and high fines by local authorities. Due to the complexity of the regulations and reporting requirements, these institutions are facing problems to identify compliance issues, along with a lack of transparency in governance. This often leads to increased manual workload, process time and paperwork due to the complexity of their IT environment.

The integrated solution provided by NTT Group combines; the RPA tool "WinActor ® (*1) " of NTT-AT, the SMCR solution of everis, and the consulting and the integration capabilities of itelligence to achieve the combination of reducing complex manual operations and coordination of compliance-related data managed across multiple systems, such as Excel (*2) and existing systems.

This solution will initially be provided as a compliance management solution for the “Senior Managers and Certification Regime (SMCR)" in the UK and will be expanded outside the UK in response to regulations and to support clients compliance and governance management globally.

NTT helps its clients accelerate their digital transformation journey by implementing innovative technologies, such as WinActor® .

Notes:

About "WinActor® "
WinActor is a robotic process automation (RPA) tool which has been developed using the in-house technologies by NTT Access Network service system laboratories and has been achieved into commercialization.
WinActor records and automates various types of human operations such as those via Windows (*2) application, Web Application and so on. It runs automatically routine repetitive tasks and large volume works instead of or collaborating with human. Additionally, by changing the existing jobs into new automatic work style, it would bring out a large value in business perspective such as efficiency, quality and cost effectiveness without modifying any software of existing system.
WinActor has been rapidly introduced and spread since 2017 especially in the organizations which seek for “Work style revolution” regardless the type of industry and size of the company. Currently, in November end of 2019, more than 4,200 companies have introduced WinActor.
For more information, please refer to https://winactor.biz/ .

(*1) "WinActor" is a registered trademark of NTT Advanced Technology Corporation.
(*2) "Excel", “Windows” is registered trademarks or trademarks of Microsoft Corporation in the US and/or other countries.

About NTT
For more information on NTT, visit www.global.ntt/
For more information on NTT-AT, visit www.ntt-at.com/
For more information on everis, visit www.everis.com/global/en
For more information on itelligence, visit itelligencegroup.com/us/
For more information on the solution, visit uk.nttdata.com/SMCR

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye